.svg)
Jennifer L. Parenti, RN
Texas Heart Institute Positions
- Clinical Research Manager, Center for Clinical Research
Education
-
Undergraduate:
University of Oregon and College of Lake County Nursing Program
Publications
4862227
B2JSS4XR
1
alternatives-to-animal-experimentation
10
date
desc
Parenti
2044
https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22Z2KFACN7%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22ACTIV-3%5C%2FTICO%20Study%20Group%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BACTIV-3%5C%2FTICO%20Study%20Group%2C%20Rogers%2C%20A.%20J.%2C%20Wentworth%2C%20D.%20et%20al.%20%282022%29.%20The%20association%20of%20baseline%20plasma%20sars-cov-2%20nucleocapsid%20antigen%20level%20and%20outcomes%20in%20patients%20hospitalized%20with%20COVID-19.%20%26lt%3Bi%26gt%3BAnn%20Intern%20Med%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B175%26lt%3B%5C%2Fi%26gt%3B%2C%201401%26%23x2013%3B1410.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM22-0924%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM22-0924%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20association%20of%20baseline%20plasma%20sars-cov-2%20nucleocapsid%20antigen%20level%20and%20outcomes%20in%20patients%20hospitalized%20with%20COVID-19%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ACTIV-3%5C%2FTICO%20Study%20Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%20J.%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deborah%22%2C%22lastName%22%3A%22Wentworth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Phillips%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katy%22%2C%22lastName%22%3A%22Shaw-Saliba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%20L.%22%2C%22lastName%22%3A%22Dewar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neil%20R.%22%2C%22lastName%22%3A%22Aggarwal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdel%20G.%22%2C%22lastName%22%3A%22Babiker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Weizhong%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nila%20J.%22%2C%22lastName%22%3A%22Dharan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victoria%20J.%22%2C%22lastName%22%3A%22Davey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20S.%22%2C%22lastName%22%3A%22Higgs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norman%22%2C%22lastName%22%3A%22Gerry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adit%20A.%22%2C%22lastName%22%3A%22Ginde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20W.%20Awori%22%2C%22lastName%22%3A%22Hayanga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Highbarger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeroen%20L.%22%2C%22lastName%22%3A%22Highbarger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mamta%20K.%22%2C%22lastName%22%3A%22Jain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginia%22%2C%22lastName%22%3A%22Kan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kami%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perrine%22%2C%22lastName%22%3A%22Lallemand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bradley%20G.%22%2C%22lastName%22%3A%22Leshnower%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20K.%22%2C%22lastName%22%3A%22Lutaakome%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gail%22%2C%22lastName%22%3A%22Matthews%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmad%22%2C%22lastName%22%3A%22Mourad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eleftherios%22%2C%22lastName%22%3A%22Mylonakis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ven%22%2C%22lastName%22%3A%22Natarajan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20L.%22%2C%22lastName%22%3A%22Padilla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lavannya%20M.%22%2C%22lastName%22%3A%22Pandit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%22%2C%22lastName%22%3A%22Paredes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Pett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Srikanth%22%2C%22lastName%22%3A%22Ramachandruni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20Tauseef%22%2C%22lastName%22%3A%22Rehman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brad%20T.%22%2C%22lastName%22%3A%22Sherman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20Clark%22%2C%22lastName%22%3A%22Files%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20M.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20A.%22%2C%22lastName%22%3A%22Matthay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20Taylor%22%2C%22lastName%22%3A%22Thompson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20D.%22%2C%22lastName%22%3A%22Neaton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20Clifford%22%2C%22lastName%22%3A%22Lane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jens%20D.%22%2C%22lastName%22%3A%22Lundgren%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Levels%20of%20plasma%20SARS-CoV-2%20nucleocapsid%20%28N%29%20antigen%20may%20be%20an%20important%20biomarker%20in%20patients%20with%20COVID-19%20and%20enhance%20our%20understanding%20of%20the%20pathogenesis%20of%20COVID-19.%5CnOBJECTIVE%3A%20To%20evaluate%20whether%20levels%20of%20plasma%20antigen%20can%20predict%20short-term%20clinical%20outcomes%20and%20identify%20clinical%20and%20viral%20factors%20associated%20with%20plasma%20antigen%20levels%20in%20hospitalized%20patients%20with%20SARS-CoV-2.%5CnDESIGN%3A%20Cross-sectional%20study%20of%20baseline%20plasma%20antigen%20level%20from%202540%20participants%20enrolled%20in%20the%20TICO%20%28Therapeutics%20for%20Inpatients%20With%20COVID-19%29%20platform%20trial%20from%20August%202020%20to%20November%202021%2C%20with%20additional%20data%20on%20day%205%20outcome%20and%20time%20to%20discharge.%5CnSETTING%3A%20114%20centers%20in%2010%20countries.%5CnPARTICIPANTS%3A%20Adults%20hospitalized%20for%20acute%20SARS-CoV-2%20infection%20with%2012%20days%20or%20less%20of%20symptoms.%5CnMEASUREMENTS%3A%20Baseline%20plasma%20viral%20N%20antigen%20level%20was%20measured%20at%20a%20central%20laboratory.%20Delta%20variant%20status%20was%20determined%20from%20baseline%20nasal%20swabs%20using%20reverse%20transcriptase%20polymerase%20chain%20reaction.%20Associations%20between%20baseline%20patient%20characteristics%20and%20viral%20factors%20and%20baseline%20plasma%20antigen%20levels%20were%20assessed%20using%20both%20unadjusted%20and%20multivariable%20modeling.%20Association%20between%20elevated%20baseline%20antigen%20level%20of%201000%20ng%5C%2FL%20or%20greater%20and%20outcomes%2C%20including%20worsening%20of%20ordinal%20pulmonary%20scale%20at%20day%205%20and%20time%20to%20hospital%20discharge%2C%20were%20evaluated%20using%20logistic%20regression%20and%20Fine-Gray%20regression%20models%2C%20respectively.%5CnRESULTS%3A%20Plasma%20antigen%20was%20below%20the%20level%20of%20quantification%20in%205%25%20of%20participants%20at%20enrollment%2C%20and%201000%20ng%5C%2FL%20or%20greater%20in%2057%25.%20Baseline%20pulmonary%20severity%20of%20illness%20was%20strongly%20associated%20with%20plasma%20antigen%20level%2C%20with%20mean%20plasma%20antigen%20level%203.10-fold%20higher%20among%20those%20requiring%20noninvasive%20ventilation%20or%20high-flow%20nasal%20cannula%20compared%20with%20room%20air%20%2895%25%20CI%2C%202.22%20to%204.34%29.%20Plasma%20antigen%20level%20was%20higher%20in%20those%20who%20lacked%20antispike%20antibodies%20%286.42%20fold%3B%20CI%2C%205.37%20to%207.66%29%20and%20in%20those%20with%20the%20Delta%20variant%20%281.73%20fold%3B%20CI%2C%201.41%20to%202.13%29.%20Additional%20factors%20associated%20with%20higher%20baseline%20antigen%20level%20included%20male%20sex%2C%20shorter%20time%20since%20hospital%20admission%2C%20decreased%20days%20of%20remdesivir%2C%20and%20renal%20impairment.%20In%20contrast%2C%20race%2C%20ethnicity%2C%20body%20mass%20index%2C%20and%20immunocompromising%20conditions%20were%20not%20associated%20with%20plasma%20antigen%20levels.%20Plasma%20antigen%20level%20of%201000%20ng%5C%2FL%20or%20greater%20was%20associated%20with%20a%20markedly%20higher%20odds%20of%20worsened%20pulmonary%20status%20at%20day%205%20%28odds%20ratio%2C%205.06%20%5BCI%2C%203.41%20to%207.50%5D%29%20and%20longer%20time%20to%20hospital%20discharge%20%28median%2C%207%20vs.%204%20days%3B%20subhazard%20ratio%2C%200.51%20%5BCI%2C%200.45%20to%200.57%5D%29%2C%20with%20subhazard%20ratios%20similar%20across%20all%20levels%20of%20baseline%20pulmonary%20severity.%5CnLIMITATIONS%3A%20Plasma%20samples%20were%20drawn%20at%20enrollment%2C%20not%20hospital%20presentation.%20No%20point-of-care%20test%20to%20measure%20plasma%20antigen%20is%20currently%20available.%5CnCONCLUSION%3A%20Elevated%20plasma%20antigen%20is%20highly%20associated%20with%20both%20severity%20of%20pulmonary%20illness%20and%20clinically%20important%20patient%20outcomes.%20Multiple%20clinical%20and%20viral%20factors%20are%20associated%20with%20plasma%20antigen%20level%20at%20presentation.%20These%20data%20support%20a%20potential%20role%20of%20ongoing%20viral%20replication%20in%20the%20pathogenesis%20of%20SARS-CoV-2%20in%20hospitalized%20patients.%5CnPRIMARY%20FUNDING%20SOURCE%3A%20U.S.%20government%20Operation%20Warp%20Speed%20and%20National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases.%22%2C%22date%22%3A%22Oct%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.7326%5C%2FM22-0924%22%2C%22ISSN%22%3A%221539-3704%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228HHBIBI6%22%2C%22849YWXRD%22%2C%22B2JSS4XR%22%2C%22QSVIJDTT%22%2C%22KXW8KUFU%22%2C%22QU9YAHAV%22%2C%22ZEQKP47S%22%2C%22F4SX9Z9X%22%2C%22FA6KSIY7%22%2C%22BULWH4DD%22%2C%22GVTR6QC3%22%5D%2C%22dateModified%22%3A%222023-02-14T20%3A20%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22PFYV7KEN%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22ACTIV-3%5C%2FTICO%20Study%20Group%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BACTIV-3%5C%2FTICO%20Study%20Group%2C%20Barkauskas%2C%20C.%2C%20Mylonakis%2C%20E.%20et%20al.%20%282022%29.%20Efficacy%20and%20safety%20of%20ensovibep%20for%20adults%20hospitalized%20with%20COVID-19%3A%20a%20randomized%20controlled%20trial.%20%26lt%3Bi%26gt%3BAnn%20Intern%20Med%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B175%26lt%3B%5C%2Fi%26gt%3B%2C%201266%26%23x2013%3B1274.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM22-1503%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM22-1503%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%20and%20safety%20of%20ensovibep%20for%20adults%20hospitalized%20with%20COVID-19%3A%20a%20randomized%20controlled%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ACTIV-3%5C%2FTICO%20Study%20Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christina%22%2C%22lastName%22%3A%22Barkauskas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eleftherios%22%2C%22lastName%22%3A%22Mylonakis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Garyfallia%22%2C%22lastName%22%3A%22Poulakou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barnaby%20E.%22%2C%22lastName%22%3A%22Young%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20M.%22%2C%22lastName%22%3A%22Vock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lianne%22%2C%22lastName%22%3A%22Siegel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Engen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Greg%22%2C%22lastName%22%3A%22Grandits%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nilima%20R.%22%2C%22lastName%22%3A%22Mosaly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20M.%22%2C%22lastName%22%3A%22Vekstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fadi%22%2C%22lastName%22%3A%22Shehadeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%22%2C%22lastName%22%3A%22Kaczynski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Evangelia%20K.%22%2C%22lastName%22%3A%22Mylona%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Konstantinos%20N.%22%2C%22lastName%22%3A%22Syrigos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vasiliki%22%2C%22lastName%22%3A%22Rapti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20C.%22%2C%22lastName%22%3A%22Lye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diong%20Shiau%22%2C%22lastName%22%3A%22Hui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lindsay%22%2C%22lastName%22%3A%22Leither%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kirk%20U.%22%2C%22lastName%22%3A%22Knowlton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mamta%20K.%22%2C%22lastName%22%3A%22Jain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rubria%22%2C%22lastName%22%3A%22Marines-Price%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Osuji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Scott%22%2C%22lastName%22%3A%22Overcash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ioannis%22%2C%22lastName%22%3A%22Kalomenidis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zafeiria%22%2C%22lastName%22%3A%22Barmparessou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Waters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karla%22%2C%22lastName%22%3A%22Zepeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sam%22%2C%22lastName%22%3A%22Torbati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francis%22%2C%22lastName%22%3A%22Kiweewa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholus%22%2C%22lastName%22%3A%22Sebudde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eyad%22%2C%22lastName%22%3A%22Almasri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alyssa%22%2C%22lastName%22%3A%22Hughes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjay%20R.%22%2C%22lastName%22%3A%22Bhagani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alison%22%2C%22lastName%22%3A%22Rodger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Uriel%22%2C%22lastName%22%3A%22Sandkovsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20L.%22%2C%22lastName%22%3A%22Gottlieb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eriobu%22%2C%22lastName%22%3A%22Nnakelu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Trautner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vidya%22%2C%22lastName%22%3A%22Menon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Lutaakome%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Matthay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Robinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Konstantinos%22%2C%22lastName%22%3A%22Protopapas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikolaos%22%2C%22lastName%22%3A%22Koulouris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivan%22%2C%22lastName%22%3A%22Kimuli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amiran%22%2C%22lastName%22%3A%22Baduashvili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%20L.%22%2C%22lastName%22%3A%22Braun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Huldrych%20F.%22%2C%22lastName%22%3A%22G%5Cu00fcnthard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Srikanth%22%2C%22lastName%22%3A%22Ramachandruni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Kidega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kami%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20J.%22%2C%22lastName%22%3A%22Hatlen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20N.%22%2C%22lastName%22%3A%22Phillips%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20D.%22%2C%22lastName%22%3A%22Murray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomas%20O.%22%2C%22lastName%22%3A%22Jensen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20L.%22%2C%22lastName%22%3A%22Padilla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Evan%20X.%22%2C%22lastName%22%3A%22Accardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katy%22%2C%22lastName%22%3A%22Shaw-Saliba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%20L.%22%2C%22lastName%22%3A%22Dewar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Teitelbaum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ven%22%2C%22lastName%22%3A%22Natarajan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Laverdure%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%20C.%22%2C%22lastName%22%3A%22Highbarger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20Tauseef%22%2C%22lastName%22%3A%22Rehman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%22%2C%22lastName%22%3A%22Vogel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Vall%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Page%22%2C%22lastName%22%3A%22Crew%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Negin%22%2C%22lastName%22%3A%22Atri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%20J.%22%2C%22lastName%22%3A%22Schechner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Pett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fleur%22%2C%22lastName%22%3A%22Hudson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Badrock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giota%22%2C%22lastName%22%3A%22Touloumi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20M.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wesley%20H.%22%2C%22lastName%22%3A%22Self%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Crystal%20M.%22%2C%22lastName%22%3A%22North%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adit%20A.%22%2C%22lastName%22%3A%22Ginde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christina%20C.%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Kelleher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Nagy-Agren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shikha%22%2C%22lastName%22%3A%22Vasudeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Looney%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hien%20H.%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%22%2C%22lastName%22%3A%22S%5Cu00e1nchez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20C.%22%2C%22lastName%22%3A%22Weintrob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Birgit%22%2C%22lastName%22%3A%22Grund%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shweta%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cavan%20S.%22%2C%22lastName%22%3A%22Reilly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%22%2C%22lastName%22%3A%22Paredes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnieszka%22%2C%22lastName%22%3A%22Bednarska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norman%20P.%22%2C%22lastName%22%3A%22Gerry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdel%20G.%22%2C%22lastName%22%3A%22Babiker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victoria%20J.%22%2C%22lastName%22%3A%22Davey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annetine%20C.%22%2C%22lastName%22%3A%22Gelijns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20S.%22%2C%22lastName%22%3A%22Higgs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginia%22%2C%22lastName%22%3A%22Kan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gail%22%2C%22lastName%22%3A%22Matthews%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20Taylor%22%2C%22lastName%22%3A%22Thompson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Legenne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richa%22%2C%22lastName%22%3A%22Chandra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20Clifford%22%2C%22lastName%22%3A%22Lane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20D.%22%2C%22lastName%22%3A%22Neaton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jens%20D.%22%2C%22lastName%22%3A%22Lundgren%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Ensovibep%20%28MP0420%29%20is%20a%20designed%20ankyrin%20repeat%20protein%2C%20a%20novel%20class%20of%20engineered%20proteins%2C%20under%20investigation%20as%20a%20treatment%20of%20SARS-CoV-2%20infection.%5CnOBJECTIVE%3A%20To%20investigate%20if%20ensovibep%2C%20in%20addition%20to%20remdesivir%20and%20other%20standard%20care%2C%20improves%20clinical%20outcomes%20among%20patients%20hospitalized%20with%20COVID-19%20compared%20with%20standard%20care%20alone.%5CnDESIGN%3A%20Double-blind%2C%20randomized%2C%20placebo-controlled%2C%20clinical%20trial.%20%28ClinicalTrials.gov%3A%20NCT04501978%29.%5CnSETTING%3A%20Multinational%2C%20multicenter%20trial.%5CnPARTICIPANTS%3A%20Adults%20hospitalized%20with%20COVID-19.%5CnINTERVENTION%3A%20Intravenous%20ensovibep%2C%20600%20mg%2C%20or%20placebo.%5CnMEASUREMENTS%3A%20Ensovibep%20was%20assessed%20for%20early%20futility%20on%20the%20basis%20of%20pulmonary%20ordinal%20scores%20at%20day%205.%20The%20primary%20outcome%20was%20time%20to%20sustained%20recovery%20through%20day%2090%2C%20defined%20as%2014%20consecutive%20days%20at%20home%20or%20place%20of%20usual%20residence%20after%20hospital%20discharge.%20A%20composite%20safety%20outcome%20that%20included%20death%2C%20serious%20adverse%20events%2C%20end-organ%20disease%2C%20and%20serious%20infections%20was%20assessed%20through%20day%2090.%5CnRESULTS%3A%20An%20independent%20data%20and%20safety%20monitoring%20board%20recommended%20that%20enrollment%20be%20halted%20for%20early%20futility%20after%20485%20patients%20were%20randomly%20assigned%20and%20received%20an%20infusion%20of%20ensovibep%20%28n%5Cu00a0%3D%5Cu00a0247%29%20or%20placebo%20%28n%5Cu00a0%3D%5Cu00a0238%29.%20The%20odds%20ratio%20%28OR%29%20for%20a%20more%20favorable%20pulmonary%20outcome%20in%20the%20ensovibep%20%28vs.%20placebo%29%20group%20at%20day%205%20was%200.93%20%2895%25%20CI%2C%200.67%20to%201.30%3B%20P%5Cu00a0%3D%5Cu00a00.68%3B%20OR%5Cu00a0%26gt%3B%5Cu00a01%20would%20favor%20ensovibep%29.%20The%2090-day%20cumulative%20incidence%20of%20sustained%20recovery%20was%2082%25%20for%20ensovibep%20and%2080%25%20for%20placebo%20%28subhazard%20ratio%20%5BsHR%5D%2C%201.06%20%5BCI%2C%200.88%20to%201.28%5D%3B%20sHR%5Cu00a0%26gt%3B%5Cu00a01%20would%20favor%20ensovibep%29.%20The%20primary%20composite%20safety%20outcome%20at%20day%2090%20occurred%20in%2078%20ensovibep%20participants%20%2832%25%29%20and%2070%20placebo%20participants%20%2829%25%29%20%28HR%2C%201.07%20%5BCI%2C%200.77%20to%201.47%5D%3B%20HR%5Cu00a0%26lt%3B%5Cu00a01%20would%20favor%20ensovibep%29.%5CnLIMITATION%3A%20The%20trial%20was%20prematurely%20stopped%20because%20of%20futility%2C%20limiting%20power%20for%20the%20primary%20outcome.%5CnCONCLUSION%3A%20Compared%20with%20placebo%2C%20ensovibep%20did%20not%20improve%20clinical%20outcomes%20for%20hospitalized%20participants%20with%20COVID-19%20receiving%20standard%20care%2C%20including%20remdesivir%3B%20no%20safety%20concerns%20were%20identified.%5CnPRIMARY%20FUNDING%20SOURCE%3A%20National%20Institutes%20of%20Health.%22%2C%22date%22%3A%22Sept%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.7326%5C%2FM22-1503%22%2C%22ISSN%22%3A%221539-3704%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228HHBIBI6%22%2C%22849YWXRD%22%2C%22UCRZ9WV2%22%2C%22B2JSS4XR%22%2C%22QSVIJDTT%22%2C%22QU9YAHAV%22%2C%22ZEQKP47S%22%2C%22F4SX9Z9X%22%2C%22FA6KSIY7%22%2C%22BULWH4DD%22%2C%22GVTR6QC3%22%5D%2C%22dateModified%22%3A%222023-02-14T20%3A14%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22RZHSHNHU%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chen%20et%20al.%22%2C%22parsedDate%22%3A%222021-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BChen%2C%20Q.%2C%20Pollet%2C%20M.%2C%20Mehta%2C%20A.%20et%20al.%20%282021%29.%20Delayed%20removal%20of%20a%20percutaneous%20left%20ventricular%20assist%20device%20for%20patients%20undergoing%20catheter%20ablation%20of%20ventricular%20tachycardia%20is%20associated%20with%20increased%2090-day%20mortality.%20%26lt%3Bi%26gt%3BJ%20Interv%20Card%20Electrophysiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B62%26lt%3B%5C%2Fi%26gt%3B%2C%2049%26%23x2013%3B56.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10840-020-00875-y%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10840-020-00875-y%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Delayed%20removal%20of%20a%20percutaneous%20left%20ventricular%20assist%20device%20for%20patients%20undergoing%20catheter%20ablation%20of%20ventricular%20tachycardia%20is%20associated%20with%20increased%2090-day%20mortality%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qi%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Pollet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adwait%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shuyu%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Dean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Parenti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francia%22%2C%22lastName%22%3A%22Rojas-Delgado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leo%22%2C%22lastName%22%3A%22Simpson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jie%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nilesh%22%2C%22lastName%22%3A%22Mathuria%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Assess%20if%20timing%20of%20removal%20of%20a%20percutaneous%20left%20ventricular%20assist%20device%20%28pLVAD%29%20after%20ventricular%20tachycardia%20%28VT%29%20ablation%20alters%20patient%20outcomes.%5CnMETHODS%3A%20Sixty-nine%20patients%20underwent%20pLVAD%20support.%20Patients%20were%20divided%20into%20early%20%28%26lt%3B%5Cu200924%5Cu00a0h%2C%20n%5Cu00a0%3D%5Cu200943%29%20and%20delayed%20%28%5Cu2265%5Cu200924%5Cu00a0h%2C%20n%5Cu00a0%3D%5Cu200926%29%20removal%20groups%20after%20ablation.%20Factors%20for%20delayed%20pLVAD%20removal%20and%20predictors%20of%2090-day%20mortality%20were%20analyzed.%5CnRESULTS%3A%20The%20delayed%20removal%20group%20had%20lower%20LVEF%20%2827.1%5Cu2009%5Cu00b1%5Cu20099.3%25%20vs.%2020.6%5Cu2009%5Cu00b1%5Cu20095.4%25%2C%20p%5Cu2009%3D%5Cu20090.002%29%2C%20greater%20percentage%20LVEF%20%26lt%3B%5Cu200925%25%20%2858.1%25%20vs.%2084.6%25%2C%20p%5Cu2009%3D%5Cu20090.02%29%2C%20and%20more%20VT%20storm%20%2841.9%25%20vs.%2096.2%25%2C%20p%5Cu2009%26lt%3B%5Cu20090.001%29.%20Ventricular%20fibrillation%20%28VF%29%20was%20induced%20in%209%5C%2F69%20%2813%25%29%2C%20with%20incidence%20higher%20in%20delayed%20removal%20group%20%2827%25%20vs.%205%25%2C%20p%5Cu2009%3D%5Cu20090.002%29.%20VT%20storm%20%28OR%5Cu2009%3D%5Cu200934.72%2C%2095%25%20CI%2C%204.30-280.33%3B%20p%5Cu2009%3D%5Cu20090.001%29%2C%20LVEF%20%26lt%3B%5Cu200925%25%20%28OR%5Cu2009%3D%5Cu20093.95%2C%2095%25%20CI%2C%201.16-13.48%3B%20p%5Cu2009%3D%5Cu20090.03%29%2C%20and%20VF%20induced%20during%20ablation%20%28OR%5Cu2009%3D%5Cu20099.25%2C%2095%25%20CI%2C%201.71-50.0%3B%20p%5Cu2009%3D%5Cu20090.01%29%20were%20associated%20with%20delayed%20pLVAD%20removal%20in%20univariate%20analysis.%20Delayed%20pLVAD%20removal%20had%20a%20significantly%20higher%2090-day%20mortality%20rate%20%282.3%25%20vs%2030.2%25%3B%20p%5Cu2009%26lt%3B%5Cu20090.001%29.%20Univariate%20Cox%20proportional%20hazard%20regression%20analysis%20revealed%20delayed%20pLVAD%20removal%20was%20a%20significant%20predictor%20of%2090-day%20mortality.%5CnCONCLUSIONS%3A%20Prolonged%20pLVAD%20insertion%20%28%5Cu2265%5Cu00a024%5Cu00a0h%29%20after%20VT%20ablation%20was%20associated%20with%20VT%20storm%2C%20LVEF%20%26lt%3B%5Cu200925%25%2C%20and%20VF%20induced%20during%20ablation.%20Delayed%20pLVAD%20removal%20was%20a%20significant%20predictor%20of%2090-day%20mortality%20in%20patients%20undergoing%20VT%20ablation.%22%2C%22date%22%3A%22Oct%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10840-020-00875-y%22%2C%22ISSN%22%3A%221572-8595%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228EPJLFD3%22%2C%22AAQ89W3S%22%2C%22CEPAWXUI%22%2C%22B2JSS4XR%22%2C%22R4DG8MRF%22%2C%226CLB47ZH%22%5D%2C%22dateModified%22%3A%222021-10-07T17%3A45%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22TSBBDPJ2%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Popma%20et%20al.%22%2C%22parsedDate%22%3A%222014-05-20%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPopma%2C%20J.%20J.%2C%20Adams%2C%20D.%20H.%2C%20Reardon%2C%20M.%20J.%20et%20al.%20%282014%29.%20Transcatheter%20aortic%20valve%20replacement%20using%20a%20self-expanding%20bioprosthesis%20in%20patients%20with%20severe%20aortic%20stenosis%20at%20extreme%20risk%20for%20surgery.%20%26lt%3Bi%26gt%3BJ%20Am%20Coll%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B63%26lt%3B%5C%2Fi%26gt%3B%2C%201972%26%23x2013%3B1981.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2014.02.556%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2014.02.556%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Transcatheter%20aortic%20valve%20replacement%20using%20a%20self-expanding%20bioprosthesis%20in%20patients%20with%20severe%20aortic%20stenosis%20at%20extreme%20risk%20for%20surgery%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20J.%22%2C%22lastName%22%3A%22Popma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20H.%22%2C%22lastName%22%3A%22Adams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Reardon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20J.%22%2C%22lastName%22%3A%22Yakubov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neal%20S.%22%2C%22lastName%22%3A%22Kleiman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Heimansohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Hermiller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Chad%22%2C%22lastName%22%3A%22Hughes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Kevin%22%2C%22lastName%22%3A%22Harrison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Coselli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Diez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ali%22%2C%22lastName%22%3A%22Kafi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theodore%22%2C%22lastName%22%3A%22Schreiber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20G.%22%2C%22lastName%22%3A%22Gleason%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Conte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurice%22%2C%22lastName%22%3A%22Buchbinder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Michael%22%2C%22lastName%22%3A%22Deeb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blas%5Cu00e9%22%2C%22lastName%22%3A%22Carabello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%22%2C%22lastName%22%3A%22Serruys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sharla%22%2C%22lastName%22%3A%22Chenoweth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jae%20K.%22%2C%22lastName%22%3A%22Oh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22CoreValve%20United%20States%20Clinical%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20This%20study%20sought%20to%20evaluate%20the%20safety%20and%20efficacy%20of%20the%20CoreValve%20transcatheter%20heart%20valve%20%28THV%29%20for%20the%20treatment%20of%20severe%20aortic%20stenosis%20in%20patients%20at%20extreme%20risk%20for%20surgery.%5CnBACKGROUND%3A%20Untreated%20severe%20aortic%20stenosis%20is%20a%20progressive%20disease%20with%20a%20poor%20prognosis.%20Transcatheter%20aortic%20valve%20replacement%20%28TAVR%29%20with%20a%20self-expanding%20bioprosthesis%20is%20a%20potentially%20effective%20therapy.%5CnMETHODS%3A%20We%20performed%20a%20prospective%2C%20multicenter%2C%20nonrandomized%20investigation%20evaluating%20the%20safety%20and%20efficacy%20of%20self-expanding%20TAVR%20in%20patients%20with%20symptomatic%20severe%20aortic%20stenosis%20with%20prohibitive%20risks%20for%20surgery.%20The%20primary%20endpoint%20was%20a%20composite%20of%20all-cause%20mortality%20or%20major%20stroke%20at%2012%20months%2C%20which%20was%20compared%20with%20a%20pre-specified%20objective%20performance%20goal%20%28OPG%29.%5CnRESULTS%3A%20A%20total%20of%2041%20sites%20in%20the%20United%20States%20recruited%20506%20patients%2C%20of%20whom%20489%20underwent%20attempted%20treatment%20with%20the%20CoreValve%20THV.%20The%20rate%20of%20all-cause%20mortality%20or%20major%20stroke%20at%2012%20months%20was%2026.0%25%20%28upper%202-sided%2095%25%20confidence%20bound%3A%2029.9%25%29%20versus%2043.0%25%20with%20the%20OPG%20%28p%20%26lt%3B%200.0001%29.%20Individual%2030-day%20and%2012-month%20events%20included%20all-cause%20mortality%20%288.4%25%20and%2024.3%25%2C%20respectively%29%20and%20major%20stroke%20%282.3%25%20and%204.3%25%2C%20respectively%29.%20Procedural%20events%20at%2030%20days%20included%20life-threatening%5C%2Fdisabling%20bleeding%20%2812.7%25%29%2C%20major%20vascular%20complications%20%288.2%25%29%2C%20and%20need%20for%20permanent%20pacemaker%20placement%20%2821.6%25%29.%20The%20frequency%20of%20moderate%20or%20severe%20paravalvular%20aortic%20regurgitation%20was%20lower%2012%20months%20after%20self-expanding%20TAVR%20%284.2%25%29%20than%20at%20discharge%20%2810.7%25%3B%20p%20%3D%200.004%20for%20paired%20analysis%29.%5CnCONCLUSIONS%3A%20TAVR%20with%20a%20self-expanding%20bioprosthesis%20was%20safe%20and%20effective%20in%20patients%20with%20symptomatic%20severe%20aortic%20stenosis%20at%20prohibitive%20risk%20for%20surgical%20valve%20replacement.%20%28Safety%20and%20Efficacy%20Study%20of%20the%20Medtronic%20CoreValve%20System%20in%20the%20Treatment%20of%20Symptomatic%20Severe%20Aortic%20Stenosis%20in%20High%20Risk%20and%20Very%20High%20Risk%20Subjects%20Who%20Need%20Aortic%20Valve%20Replacement%3B%20NCT01240902%29.%22%2C%22date%22%3A%22May%2020%2C%202014%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jacc.2014.02.556%22%2C%22ISSN%22%3A%221558-3597%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22BJSZ96GT%22%2C%22YL3LPZGE%22%2C%22B2JSS4XR%22%2C%22N5HQ4VYL%22%5D%2C%22dateModified%22%3A%222022-03-08T19%3A34%3A33Z%22%7D%7D%2C%7B%22key%22%3A%2272F38CCQ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Adams%20et%20al.%22%2C%22parsedDate%22%3A%222014-05-08%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAdams%2C%20D.%20H.%2C%20Popma%2C%20J.%20J.%2C%20Reardon%2C%20M.%20J.%20et%20al.%20%282014%29.%20Transcatheter%20aortic-valve%20replacement%20with%20a%20self-expanding%20prosthesis.%20%26lt%3Bi%26gt%3BN%20Engl%20J%20Med%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B370%26lt%3B%5C%2Fi%26gt%3B%2C%201790%26%23x2013%3B1798.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1056%5C%2FNEJMoa1400590%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1056%5C%2FNEJMoa1400590%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Transcatheter%20aortic-valve%20replacement%20with%20a%20self-expanding%20prosthesis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20H.%22%2C%22lastName%22%3A%22Adams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20J.%22%2C%22lastName%22%3A%22Popma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Reardon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20J.%22%2C%22lastName%22%3A%22Yakubov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20S.%22%2C%22lastName%22%3A%22Coselli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Michael%22%2C%22lastName%22%3A%22Deeb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20G.%22%2C%22lastName%22%3A%22Gleason%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurice%22%2C%22lastName%22%3A%22Buchbinder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Hermiller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neal%20S.%22%2C%22lastName%22%3A%22Kleiman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stan%22%2C%22lastName%22%3A%22Chetcuti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Heiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Merhi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Zorn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Tadros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Newell%22%2C%22lastName%22%3A%22Robinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Petrossian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Chad%22%2C%22lastName%22%3A%22Hughes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Kevin%22%2C%22lastName%22%3A%22Harrison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Conte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brijeshwar%22%2C%22lastName%22%3A%22Maini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mubashir%22%2C%22lastName%22%3A%22Mumtaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sharla%22%2C%22lastName%22%3A%22Chenoweth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jae%20K.%22%2C%22lastName%22%3A%22Oh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22U.S.%20CoreValve%20Clinical%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20We%20compared%20transcatheter%20aortic-valve%20replacement%20%28TAVR%29%2C%20using%20a%20self-expanding%20transcatheter%20aortic-valve%20bioprosthesis%2C%20with%20surgical%20aortic-valve%20replacement%20in%20patients%20with%20severe%20aortic%20stenosis%20and%20an%20increased%20risk%20of%20death%20during%20surgery.%5CnMETHODS%3A%20We%20recruited%20patients%20with%20severe%20aortic%20stenosis%20who%20were%20at%20increased%20surgical%20risk%20as%20determined%20by%20the%20heart%20team%20at%20each%20study%20center.%20Risk%20assessment%20included%20the%20Society%20of%20Thoracic%20Surgeons%20Predictor%20Risk%20of%20Mortality%20estimate%20and%20consideration%20of%20other%20key%20risk%20factors.%20Eligible%20patients%20were%20randomly%20assigned%20in%20a%201%3A1%20ratio%20to%20TAVR%20with%20the%20self-expanding%20transcatheter%20valve%20%28TAVR%20group%29%20or%20to%20surgical%20aortic-valve%20replacement%20%28surgical%20group%29.%20The%20primary%20end%20point%20was%20the%20rate%20of%20death%20from%20any%20cause%20at%201%20year%2C%20evaluated%20with%20the%20use%20of%20both%20noninferiority%20and%20superiority%20testing.%5CnRESULTS%3A%20A%20total%20of%20795%20patients%20underwent%20randomization%20at%2045%20centers%20in%20the%20United%20States.%20In%20the%20as-treated%20analysis%2C%20the%20rate%20of%20death%20from%20any%20cause%20at%201%20year%20was%20significantly%20lower%20in%20the%20TAVR%20group%20than%20in%20the%20surgical%20group%20%2814.2%25%20vs.%2019.1%25%29%2C%20with%20an%20absolute%20reduction%20in%20risk%20of%204.9%20percentage%20points%20%28upper%20boundary%20of%20the%2095%25%20confidence%20interval%2C%20-0.4%3B%20P%26lt%3B0.001%20for%20noninferiority%3B%20P%20%3D%200.04%20for%20superiority%29.%20The%20results%20were%20similar%20in%20the%20intention-to-treat%20analysis.%20In%20a%20hierarchical%20testing%20procedure%2C%20TAVR%20was%20noninferior%20with%20respect%20to%20echocardiographic%20indexes%20of%20valve%20stenosis%2C%20functional%20status%2C%20and%20quality%20of%20life.%20Exploratory%20analyses%20suggested%20a%20reduction%20in%20the%20rate%20of%20major%20adverse%20cardiovascular%20and%20cerebrovascular%20events%20and%20no%20increase%20in%20the%20risk%20of%20stroke.%5CnCONCLUSIONS%3A%20In%20patients%20with%20severe%20aortic%20stenosis%20who%20are%20at%20increased%20surgical%20risk%2C%20TAVR%20with%20a%20self-expanding%20transcatheter%20aortic-valve%20bioprosthesis%20was%20associated%20with%20a%20significantly%20higher%20rate%20of%20survival%20at%201%20year%20than%20surgical%20aortic-valve%20replacement.%20%28Funded%20by%20Medtronic%3B%20U.S.%20CoreValve%20High%20Risk%20Study%20ClinicalTrials.gov%20number%2C%20NCT01240902.%29.%22%2C%22date%22%3A%22May%2008%2C%202014%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMoa1400590%22%2C%22ISSN%22%3A%221533-4406%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22BJSZ96GT%22%2C%22B2JSS4XR%22%2C%22DF5KVMFT%22%2C%22N5HQ4VYL%22%5D%2C%22dateModified%22%3A%222022-03-08T19%3A33%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22KMANB67B%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22LeMaire%20et%20al.%22%2C%22parsedDate%22%3A%222012-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLeMaire%2C%20S.%20A.%2C%20Green%2C%20S.%20Y.%2C%20Kim%2C%20J.%20H.%20et%20al.%20%282012%29.%20Thoracic%20or%20thoracoabdominal%20approaches%20to%20endovascular%20device%20removal%20and%20open%20aortic%20repair.%20%26lt%3Bi%26gt%3BAnn%20Thorac%20Surg%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B93%26lt%3B%5C%2Fi%26gt%3B%2C%20726%26%23x2013%3B732%3B%20discussion%20733.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.athoracsur.2011.10.080%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.athoracsur.2011.10.080%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Thoracic%20or%20thoracoabdominal%20approaches%20to%20endovascular%20device%20removal%20and%20open%20aortic%20repair%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20A.%22%2C%22lastName%22%3A%22LeMaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%20Y.%22%2C%22lastName%22%3A%22Green%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jae%20Hyun%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aryan%22%2C%22lastName%22%3A%22Sameri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20L.%22%2C%22lastName%22%3A%22Parenti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20H.%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Huh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20S.%22%2C%22lastName%22%3A%22Coselli%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Endovascular%20aortic%20repair%20is%20becoming%20increasingly%20common%20and%20diverse%20in%20its%20application%20despite%20ongoing%20uncertainty%20about%20long-term%20durability.%20Recent%20reports%20detail%20late%20conversion%20to%20open%20surgical%20repair%20to%20treat%20disease%20progression%20and%20repair%20failure.%20We%20describe%20our%20experience%20with%20using%20thoracic%20or%20thoracoabdominal%20approaches%20to%20endovascular%20device%20removal%20and%20open%20aortic%20repair%20after%20previous%20endovascular%20procedures.%5CnMETHODS%3A%20Thirty-five%20patients%20underwent%20open%20aortic%20repair%20through%20thoracotomy%20%28n%3D7%29%20or%20thoracoabdominal%20incision%20%28n%3D28%29%200.5%20to%2048%20months%20after%20undergoing%20endovascular%20thoracic%20%28n%3D27%29%20or%20abdominal%20%28n%3D8%29%20aortic%20procedures.%20Indications%20for%20open%20repair%20included%20expanding%20aneurysm%20%28n%3D23%29%2C%20device%20infection%20%28n%3D8%29%2C%20fistula%20%28n%3D5%29%2C%20pseudoaneurysm%20%28n%3D2%29%2C%20aneurysm%20rupture%20%28n%3D2%29%2C%20and%20restenosis%20%28n%3D1%29.%20Endovascular%20devices%20were%20completely%20removed%20in%2026%20patients%20and%20partially%20removed%20in%209.%20Descending%20thoracic%20aortic%20repair%20was%20performed%20in%2010%20patients%2C%20thoracoabdominal%20aortic%20repair%20in%2024%2C%20and%20juxtarenal%20abdominal%20aortic%20repair%20in%201.%5CnRESULTS%3A%20There%20were%202%20in-hospital%20deaths%20%286%25%29%2C%20both%20in%20patients%20who%20presented%20with%20endovascular%20device%20infection.%20There%20were%208%20late%20deaths.%20Overall%201-year%20survival%20was%2083%25%5Cu00b17%25.%20Among%20the%20patients%20who%20presented%20with%20infected%20devices%2C%203%20experienced%20major%20late%20complications%2C%20including%20persistent%20infection%2C%20pseudoaneurysm%2C%20and%20recurrent%20fistula%3B%202%20of%20these%20patients%20succumbed%20to%20late%20deaths.%5CnCONCLUSIONS%3A%20Open%20surgical%20repair%20after%20previous%20endovascular%20aortic%20procedures%20is%20successful%20in%20the%20majority%20of%20patients%2C%20particularly%20in%20those%20without%20device%20infections.%20Achieving%20definitive%20aortic%20repair%20in%20patients%20with%20infected%20endovascular%20devices%20is%20particularly%20challenging.%22%2C%22date%22%3A%22Mar%202012%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.athoracsur.2011.10.080%22%2C%22ISSN%22%3A%221552-6259%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22BJSZ96GT%22%2C%22EBAYDVV4%22%2C%22B2JSS4XR%22%5D%2C%22dateModified%22%3A%222022-01-24T22%3A04%3A00Z%22%7D%7D%2C%7B%22key%22%3A%224A6GQRR3%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wong%20et%20al.%22%2C%22parsedDate%22%3A%222011-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWong%2C%20D.%20R.%2C%20%26lt%3Bstrong%26gt%3BParenti%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20L.%2C%20Green%2C%20S.%20Y.%20et%20al.%20%282011%29.%20Open%20repair%20of%20thoracoabdominal%20aortic%20aneurysm%20in%20the%20modern%20surgical%20era%3A%20contemporary%20outcomes%20in%20509%20patients.%20%26lt%3Bi%26gt%3BJ%20Am%20Coll%20Surg%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B212%26lt%3B%5C%2Fi%26gt%3B%2C%20569%26%23x2013%3B579%3B%20discussion%20579-581.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jamcollsurg.2010.12.041%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jamcollsurg.2010.12.041%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Open%20repair%20of%20thoracoabdominal%20aortic%20aneurysm%20in%20the%20modern%20surgical%20era%3A%20contemporary%20outcomes%20in%20509%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20R.%22%2C%22lastName%22%3A%22Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20L.%22%2C%22lastName%22%3A%22Parenti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%20Y.%22%2C%22lastName%22%3A%22Green%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Varun%22%2C%22lastName%22%3A%22Chowdhary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joshua%20M.%22%2C%22lastName%22%3A%22Liao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samantha%22%2C%22lastName%22%3A%22Zarda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Huh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20A.%22%2C%22lastName%22%3A%22LeMaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20S.%22%2C%22lastName%22%3A%22Coselli%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Recent%20technologic%20advances%20in%20endovascular%20devices%20have%20led%20to%20alternative%20approaches%20to%20thoracoabdominal%20aortic%20aneurysm%20%28TAAA%29%20repair%3B%20these%20innovative%20approaches%20must%20be%20compared%20with%20the%20%26quot%3Bgold%20standard%26quot%3B%20of%20conventional%20open%20TAAA%20repair.%20To%20facilitate%20such%20comparisons%2C%20we%20evaluated%20contemporary%20outcomes%20of%20open%20TAAA%20repair.%5CnSTUDY%20DESIGN%3A%20We%20retrospectively%20reviewed%20and%20analyzed%20data%20collected%20prospectively%20between%20May%202006%20and%20October%202010%20regarding%20509%20consecutive%20patients%20who%20underwent%20TAAA%20repair.%20Standard%20univariate%20statistical%20comparisons%20were%20performed%2C%20as%20well%20as%20multivariable%20modeling%2C%20to%20identify%20predictors%20of%20survival.%5CnRESULTS%3A%20A%20total%20of%20305%20patients%20%2859.9%25%29%20had%20degenerative%20aneurysms%20without%20dissection%2C%20and%20204%20%2840.1%25%29%20had%20aortic%20dissection.%20There%20were%20104%20%2820.4%25%29%20urgent%20or%20emergent%20repairs%20and%2026%20%285.1%25%29%20ruptured%20aneurysms.%20Operative%20adjuncts%20were%20used%20selectively.%20Of%20the%20290%20patients%20%2857.0%25%29%20who%20underwent%20extensive%20repairs%20%28Crawford%20extents%20I%20and%20II%29%2C%20282%20%2897.2%25%29%20had%20cerebrospinal%20fluid%20drainage%2C%20257%20%2888.6%25%29%20had%20left%20heart%20bypass%2C%20and%20213%20%2873.4%25%29%20had%20intercostal%5C%2Flumbar%20artery%20reattachment.%20The%20overall%20operative%20survival%20rate%20was%2092.1%25%20%28469%20of%20509%29%2C%20and%20survival%20was%20better%20after%20elective%20repairs%20%2893.8%25%20%5B380%20of%20405%5D%29%20than%20after%20urgent%20or%20emergent%20operations%20%2885.6%25%20%5B89%20of%20104%5D%2C%20p%20%3D%200.005%29.%20Renal%20failure%20necessitating%20hemodialysis%20at%20discharge%20developed%20in%2030%20patients%20%285.9%25%29.%20Permanent%20paraplegia%20occurred%20in%2013%20patients%20%282.6%25%29.%20Actuarial%20survival%20was%2079.1%25%20%5Cu00b1%202.0%25%20at%202%20years.%5CnCONCLUSIONS%3A%20Contemporary%20open%20TAAA%20repair%20is%20characterized%20by%20respectable%20early%20outcomes%2C%20particularly%20when%20repair%20is%20elective.%20Such%20results%20should%20be%20compared%20with%20those%20of%20evolving%20approaches%2C%20including%20endovascular%20and%20hybrid%20repairs.%22%2C%22date%22%3A%22Apr%202011%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jamcollsurg.2010.12.041%22%2C%22ISSN%22%3A%221879-1190%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22BJSZ96GT%22%2C%22EBAYDVV4%22%2C%22B2JSS4XR%22%5D%2C%22dateModified%22%3A%222022-01-24T21%3A24%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22IIPMPR3C%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22LeMaire%20et%20al.%22%2C%22parsedDate%22%3A%222011-03%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLeMaire%2C%20S.%20A.%2C%20Price%2C%20M.%20D.%2C%20%26lt%3Bstrong%26gt%3BParenti%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20L.%20et%20al.%20%282011%29.%20Early%20outcomes%20after%20aortic%20arch%20replacement%20by%20using%20the%20Y-graft%20technique.%20%26lt%3Bi%26gt%3BAnn%20Thorac%20Surg%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B91%26lt%3B%5C%2Fi%26gt%3B%2C%20700%26%23x2013%3B707%3B%20discussion%20707-708.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.athoracsur.2010.11.008%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.athoracsur.2010.11.008%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Early%20outcomes%20after%20aortic%20arch%20replacement%20by%20using%20the%20Y-graft%20technique%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20A.%22%2C%22lastName%22%3A%22LeMaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matt%20D.%22%2C%22lastName%22%3A%22Price%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20L.%22%2C%22lastName%22%3A%22Parenti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20L.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicia%20D.%22%2C%22lastName%22%3A%22Lay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ourania%22%2C%22lastName%22%3A%22Preventza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Huh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20S.%22%2C%22lastName%22%3A%22Coselli%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Aortic%20arch%20replacement%20remains%20among%20the%20most%20technically%20challenging%20cardiovascular%20operations%2C%20incurring%20considerable%20risk%20for%20perioperative%20death%20and%20stroke.%20The%20trifurcated%20graft%20technique%2C%20in%20which%20a%20double%20Y-graft%20is%20used%20to%20connect%20brachiocephalic%20branches%20to%20the%20main%20aortic%20graft%2C%20was%20recently%20developed%20to%20simplify%20arch%20reconstruction%2C%20reduce%20embolization%2C%20and%20minimize%20related%20cerebral%20ischemia.%20We%20examined%20early%20outcomes%20of%20aortic%20arch%20replacement%20performed%20by%20using%20single%20or%20double%20Y-graft%20variations%20of%20this%20technique.%5CnMETHODS%3A%20Between%20December%202006%20and%20May%202009%2C%20the%20Y-graft%20technique%20was%20used%20to%20perform%20aortic%20arch%20replacement%20in%2055%20patients.%20Thirty-three%20patients%20had%20prior%20median%20sternotomy%20%2860%25%29%2C%20and%2034%20%2862%25%29%20had%20ascending%20aortic%20dissection.%20Axillary%20cannulation%20was%20used%20in%2052%20patients%20%2895%25%29%2C%20and%20hypothermic%20circulatory%20arrest%20and%20antegrade%20cerebral%20perfusion%20were%20used%20in%20all%20patients.%20Median%20systemic%20and%20cerebral%20circulatory%20arrest%20times%20were%2065%20minutes%20and%200%20minutes%2C%20respectively.%20A%20first-stage%20elephant%20trunk%20repair%20was%20performed%20in%2046%20patients%20%2884%25%29.%20Follow-up%20data%20were%20obtained%20for%20all%20patients.%5CnRESULTS%3A%20There%20were%20no%20in-hospital%20deaths%20and%20one%2030-day%20death%20%282%25%29.%20Three%20patients%20%285%25%29%20had%20strokes%2C%201%20of%20which%20was%20transient.%20Actuarial%201-year%20and%202-year%20survival%20rates%20were%2080.0%25%20%5Cu00b1%205.4%25%20and%2077.6%25%20%5Cu00b1%205.7%25%2C%20respectively.%20Thirty-one%20of%20the%20elephant%20trunk%20patients%20%2867%25%29%20subsequently%20underwent%20second-stage%20completion%20procedures%2C%205%20%2816%25%29%20of%20them%20endovascular.%5CnCONCLUSIONS%3A%20Early%20results%20of%20aortic%20arch%20replacement%20by%20the%20Y-graft%20technique%20compare%20favorably%20with%20those%20of%20traditional%20approaches.%20The%20technique%20enables%20effective%20delivery%20of%20antegrade%20cerebral%20perfusion%20during%20complex%20arch%20procedures%20and%20incurs%20only%20a%20low%20risk%20of%20neurologic%20sequelae.%22%2C%22date%22%3A%22Mar%202011%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.athoracsur.2010.11.008%22%2C%22ISSN%22%3A%221552-6259%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SQD2CTYV%22%2C%22BJSZ96GT%22%2C%22EBAYDVV4%22%2C%22B2JSS4XR%22%5D%2C%22dateModified%22%3A%222022-02-14T21%3A12%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22XG54FL9J%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Naoum%20et%20al.%22%2C%22parsedDate%22%3A%222008-03%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BNaoum%2C%20J.%20J.%2C%20%26lt%3Bstrong%26gt%3BParenti%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20L.%2C%20LeMaire%2C%20S.%20A.%20et%20al.%20%282008%29.%20Endovascular%20repair%20of%20a%20right-sided%20descending%20thoracic%20aortic%20aneurysm%20with%20a%20right-sided%20aortic%20arch%20and%20aberrant%20left%20subclavian%20artery.%20%26lt%3Bi%26gt%3BAnn%20Thorac%20Surg%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B85%26lt%3B%5C%2Fi%26gt%3B%2C%201074%26%23x2013%3B1076.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.athoracsur.2007.09.032%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.athoracsur.2007.09.032%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Endovascular%20repair%20of%20a%20right-sided%20descending%20thoracic%20aortic%20aneurysm%20with%20a%20right-sided%20aortic%20arch%20and%20aberrant%20left%20subclavian%20artery%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20J.%22%2C%22lastName%22%3A%22Naoum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20L.%22%2C%22lastName%22%3A%22Parenti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20A.%22%2C%22lastName%22%3A%22LeMaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20S.%22%2C%22lastName%22%3A%22Coselli%22%7D%5D%2C%22abstractNote%22%3A%22Aneurysms%20involving%20a%20right-sided%20aortic%20arch%20and%20a%20right-sided%20descending%20thoracic%20aorta%20with%20an%20aberrant%20origin%20of%20the%20left%20subclavian%20artery%20are%20rare.%20We%20describe%20the%20successful%20surgical%20repair%20of%20this%20vascular%20anomaly%20by%20the%20combined%20use%20of%20a%20left%20carotid%20to%20subclavian%20artery%20bypass%20followed%20by%20endovascular%20stent-graft%20placement%20to%20exclude%20the%20aortic%20aneurysm.%20We%20also%20review%20the%20literature%20associated%20with%20this%20particular%20anatomic%20presentation.%22%2C%22date%22%3A%22Mar%202008%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.athoracsur.2007.09.032%22%2C%22ISSN%22%3A%221552-6259%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22BJSZ96GT%22%2C%22EBAYDVV4%22%2C%22B2JSS4XR%22%5D%2C%22dateModified%22%3A%222022-02-08T19%3A00%3A09Z%22%7D%7D%5D%7D
ACTIV-3/TICO Study Group, Rogers, A. J., Wentworth, D. et al. (2022). The association of baseline plasma sars-cov-2 nucleocapsid antigen level and outcomes in patients hospitalized with COVID-19. Ann Intern Med 175, 1401–1410. https://doi.org/10.7326/M22-0924.
ACTIV-3/TICO Study Group, Barkauskas, C., Mylonakis, E. et al. (2022). Efficacy and safety of ensovibep for adults hospitalized with COVID-19: a randomized controlled trial. Ann Intern Med 175, 1266–1274. https://doi.org/10.7326/M22-1503.
Chen, Q., Pollet, M., Mehta, A. et al. (2021). Delayed removal of a percutaneous left ventricular assist device for patients undergoing catheter ablation of ventricular tachycardia is associated with increased 90-day mortality. J Interv Card Electrophysiol 62, 49–56. https://doi.org/10.1007/s10840-020-00875-y.
Popma, J. J., Adams, D. H., Reardon, M. J. et al. (2014). Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 63, 1972–1981. https://doi.org/10.1016/j.jacc.2014.02.556.
Adams, D. H., Popma, J. J., Reardon, M. J. et al. (2014). Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370, 1790–1798. https://doi.org/10.1056/NEJMoa1400590.
LeMaire, S. A., Green, S. Y., Kim, J. H. et al. (2012). Thoracic or thoracoabdominal approaches to endovascular device removal and open aortic repair. Ann Thorac Surg 93, 726–732; discussion 733. https://doi.org/10.1016/j.athoracsur.2011.10.080.
Wong, D. R., Parenti, J. L., Green, S. Y. et al. (2011). Open repair of thoracoabdominal aortic aneurysm in the modern surgical era: contemporary outcomes in 509 patients. J Am Coll Surg 212, 569–579; discussion 579-581. https://doi.org/10.1016/j.jamcollsurg.2010.12.041.
LeMaire, S. A., Price, M. D., Parenti, J. L. et al. (2011). Early outcomes after aortic arch replacement by using the Y-graft technique. Ann Thorac Surg 91, 700–707; discussion 707-708. https://doi.org/10.1016/j.athoracsur.2010.11.008.
Naoum, J. J., Parenti, J. L., LeMaire, S. A. et al. (2008). Endovascular repair of a right-sided descending thoracic aortic aneurysm with a right-sided aortic arch and aberrant left subclavian artery. Ann Thorac Surg 85, 1074–1076. https://doi.org/10.1016/j.athoracsur.2007.09.032.
